行情

KZIA

KZIA

Kazia
NASDAQ

实时行情|Nasdaq Last Sale

4.060
+0.018
+0.44%
休市 16:00 02/21 EST
开盘
4.090
昨收
4.042
最高
4.110
最低
3.980
成交量
5,823
成交额
--
52周最高
9.74
52周最低
2.240
市值
2,523.97万
市盈率(TTM)
-3.2629
分时
5日
1月
3月
1年
5年

KZIA 新闻

更多
  • 巴菲特股东信:低利率利好股市但不要借钱入场
  • 一财网 · 1分钟前
  • 巴菲特眼中的风险:决策依赖关键人物 投资集中于股票
  • 新浪美股 · 16分钟前
  • 巴菲特2020年致股东信10大看点
  • 新浪美股 · 1小时前
  • 黑田东彦对日元正失去避险资产地位的揣测进行反击
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

KZIA 简况

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
展开

微牛提供Kazia Therapeutics Ltd (ADR)(NASDAQ-KZIA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的KZIA股票新闻,以帮助您做出投资决策。